Loading the content... Loading depends on your connection speed!

Shopping Cart - $0.00

Genito-urinary Drugs Market Global Briefing 2017

Genito-urinary Drugs Market Global Briefing 2017

From $1,000.00

Including: Hormonal contraceptives, Drugs For Hormonal Replacement Therapy, Drugs For Infections And Others, Drugs for Benign prostatic hypertrophy, Drugs For Erectile Dysfunction, Drugs For Urinary Incontinence And Overactive Bladder, Drugs for Infertility, and Diuretics
Covering: Daiichi Sankyo Company, Limited, Pfizer Inc., Bayer AG, Astellas Pharma Inc., Allergan Plc., Otsuka Pharmaceutical Co., Ltd., GlaxosmithKline Plc., Sanofi S.A.


Clear selection
SKU: 2274. Categories: , .
Description

The top segments in the genito-urinary drugs market include hormonal contraceptives, drugs for hormonal replacement therapy and drugs for infections and others.

Genito-urinary Market Global Briefing from the Business Research Company covers market characteristics, size and growth, segmentation, regional breakdowns, competitive landscape, market shares, trends and strategies for this market.

The market characteristics section of the report defines and explains the market.

The market size section gives the genito-urinary drugs market revenues, covering both the historic growth of the market and forecasting the future.

Drivers and restraints looks at the external factors supporting and controlling the growth of the market.

Market segmentations break down the key sub sectors which make up the market. The regional breakdowns section gives the size of the market geographically.

Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in the last three years are identified.

The trends and strategies section highlights the likely future developments in the genito-urinary drugs market and suggests approaches.

Reasons to Purchase

• Get up to date information available on the genito-urinary drugs market globally.
• Identify growth segments and opportunities.
• Facilitate decision making on the basis of historic and forecast data and understand the drivers and restraints on the market.
• Develop strategies based on likely future developments.
• Gain a global perspective on the development of the market.

Scope

Markets Covered: Hormonal contraceptives, Drugs For Hormonal Replacement Therapy, Drugs For Infections And Others, Drugs for Benign prostatic hypertrophy, Drugs For Erectile Dysfunction, Drugs For Urinary Incontinence And Overactive Bladder, Drugs for Infertility, and Diuretics
Companies Mentioned: Daiichi Sankyo Company Limited, Pfizer Inc., Bayer AG, Astellas Pharma Inc., Allergan Plc., Otsuka Pharmaceutical Co., Ltd., GlaxosmithKline Plc., Sanofi S.A.
Geographic scope: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East And Africa
Time series: Five years historic and forecast.
Data: Market value in $ billions.
Data segmentations: Regional breakdowns, market share of competitors, key sub segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Executive Summary
The genitourinary drugs market covers drugs that are used in the treatment of diseases such as urinary tract infections, male reproductive diseases, voiding diseases, female reproductive diseases, glomerular disorders, urinary calculi, cystic kidney disease, Reno vascular diseases, benign prostate diseases, and other related diseases.

The global genito-urinary drugs market is expected to reach around $75 billion in 2020. This growth is mainly due to the growing genitourinary disorders like chronic kidney disease CKD and also going forward, the number of pipeline drugs (ABT-614, Abbott Laboratories and EOS789, Chugai Pharmaceutical) are expected to increase with constant improvements in healthcare infrastructure. Novel drugs such as Cialis which are considerably more effective than the drugs used in multiple-drug therapies, and are affordable in cost are expected to fuel the growth of this market.

Demand For Combination Products - The launch of combination products for the treatment of urinary tract infections is an emerging trend in the genito-urinary disorder drugs market. Competitors in the market are developing combination drugs to fight multi-drug resistant bacteria and also expanding indications for existing drugs for the treatment of genito-urinary disorders. For instance, Merck Sharp & Dohme Corp. offers ZERBAXA, a combination drug of a novel cephalosporin and a beta-lactamase inhibitor used for the treatment of complicated urinary tract infections.
Table of Contents
Genito-urinary Drugs Market Characteristics 5
Genito-urinary Drugs Market Historic Growth 7
Genito-urinary Drugs Market Forecast Growth 8
Genito-urinary Drugs Market Segmentation 9
Global Genito-urinary Drugs Market, Split By Segments, 2016, $ Billion 9
Hormonal Contraceptives 10
Drugs For Hormonal Replacement Therapy 10
Drugs For Infections And Others 10
Global Genito-urinary Drugs Market, Historic and Forecast, Split By Segments, 2012-2020 11
Genito-urinary Drugs Market Geography Regional and Country Comparison 13
Global Genito-urinary Drugs Market, Split By Regions, 2016 13
Global Genito-urinary Drugs Market, Historic And Forecast Growth Rate, Split By Region, 2012-2020 15
Global Genito-urinary Drugs Market, Split By Country, 2016 17
Global Genito-urinary Drugs Market, Historic And Forecast Growth Rate, Split By Country, 2012-2020 19
Genito-urinary Drugs Market Competitive Landscape 21
Pfizer Inc. 22
Daiichi Sankyo Company Limited 22
Bayer AG 22
Astellas Pharma Inc. 22
Otsuka Pharmaceutical Co., Ltd. 22
Allergan Plc. 22
GlaxosmithKline Plc. 22
Sanofi S.A. 22
Pfizer 22
Daiichi Sankyo Company Limited 23
Bayer AG 24
Genito-urinary Drugs Market Key Mergers And Acquisitions 25
Valeant Pharmaceuticals Acquired Sprout Pharmaceuticals 25
Adamis Pharmaceuticals Acquired US Compounding 25
Norgine Acquired Merus Labs 25
Astellas Acquired Ogeda 25
Genito-urinary Drugs Market Trends and Strategies 26
Demand For Combination Products 26
Increasing Demand For Low-Cost Erectile Dysfunction Drugs 26
Increase In Mergers And Acquisitions 26
Increase In The Approvals Of Novel Drugs 26
Appendix 27
Definition Of Market Covered In This Report 27
Abbreviations 27
Currencies 27
Research Methodology 27
Research Inquiries 28
The Business Research Company 28

List of Figures
Figure 1: Global Genito-urinary Drugs Market, Historic Market Size, 2012-2016, $ Billion 7
Figure 2: Global Genito-urinary Drugs Market, Forecast Market Size, 2016 – 2020, $ Billion 8
Figure 3: Global Genito-urinary Drugs Market, Split By Segments, 2016, $ Billion 9
Figure 4: Global Genito-urinary Drugs Market, Historic and Forecast, Split By Segment, 2012 – 2020 11
Figure 5: Global Genito-urinary Drugs Market, Split By Region, 2016, $ Billion 13
Figure 6: Global Genito-urinary Drugs Market, Historic And Forecast Growth Rate, Split By Region, 2012-2020 15
Figure 7: Global Genito-urinary Drugs Market, Split By Country, 2016, $ Billion 17
Figure 8: Global Genito-urinary Drugs Market, Historic And Forecast Growth Rate, Split By Country, 2012-2020 19
Figure 9: Global Genito-urinary Drugs Market, Key Competitor Market Shares, 2016, Percentage (%) 21


List of Tables
Table 1: Global Genito-urinary Drugs Market, Historic Market Size, 2012-2016, $ Billion 7
Table 2: Global Genito-urinary Drugs Market, Forecast Market Size, 2016 – 2020, $ Billion 8
Table 3: Global Genito-urinary Drugs Market, Split By Segments, 2016, $ Billion 10
Table 4: Global Genito-urinary Drugs Market, Historic and Forecast, Split By Segment, 2012 – 2020 12
Table 5: Global Genito-urinary Drugs Market, Split By Region, 2016, $ Billion 14
Table 6: Global Genito-urinary Drugs Market, Historic And Forecast Growth Rate, Split By Region, 2012-2020 15
Table 7: Global Genito-urinary Drugs Market, Split By Country, 2016, $ Billion 17
Table 8: Global Genito-urinary Drugs Market, Historic And Forecast Growth Rate, Split By Country, 2012-2020 19
Table 9: Global Genito-urinary Drugs Market, Key Competitor Market Shares, 2016, Percentage (%) 22
Get Customized Report
Please fill in your details. Our team will get back to you